Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its rivals? We will compare Axsome Therapeutics to similar companies based on the strength of its analyst recommendations, institutional ownership, dividends, valuation, earnings, profitability and risk.
Profitability
This table compares Axsome Therapeutics and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Axsome Therapeutics | -18.18% | -198.73% | -22.03% |
| Axsome Therapeutics Competitors | -2,398.26% | -203.62% | -15.08% |
Valuation and Earnings
This table compares Axsome Therapeutics and its rivals revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Axsome Therapeutics | $638.50 million | -$183.17 million | -46.30 |
| Axsome Therapeutics Competitors | $3.55 billion | $3.17 billion | 562.76 |
Axsome Therapeutics’ rivals have higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Risk & Volatility
Axsome Therapeutics has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Comparatively, Axsome Therapeutics’ rivals have a beta of -0.04, meaning that their average stock price is 104% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent recommendations for Axsome Therapeutics and its rivals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Axsome Therapeutics | 1 | 2 | 17 | 1 | 2.86 |
| Axsome Therapeutics Competitors | 7844 | 13796 | 25806 | 1039 | 2.41 |
Axsome Therapeutics presently has a consensus target price of $266.21, indicating a potential upside of 87.88%. As a group, “Pharmaceuticals” companies have a potential upside of 24.32%. Given Axsome Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Axsome Therapeutics is more favorable than its rivals.
Insider & Institutional Ownership
81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Axsome Therapeutics beats its rivals on 9 of the 12 factors compared.
About Axsome Therapeutics
Axsome Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system disorders. The company is headquartered in New York and is led by founder, chairman and chief executive officer Herriot Tabuteau. Its marketed products include Auvelity, an oral treatment for major depressive disorder in adults, and Sunosi, which is used to improve wakefulness in adults with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
